Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Depression
Interventions: duloxetine, escitalopram, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: 1. Major Depressive Disorder
Interventions: Supplemental TMS, Standard Medication Monotherapy; Device · Drug
Lead sponsor: Sheppard Pratt Health System; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Major Depressive Disorder
Interventions: Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg, placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Encino, California • Newport Beach, California + 21 more

Conditions: Major Depression
Interventions: MK-0657, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: ABX-002, Placebo; Drug · Other
Lead sponsor: Autobahn Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 44 more

Conditions: Suicidal Ideation, Major Depressive Disorder
Interventions: Dialectical Behavior Therapy Skills (DBT-S) Groups, Wait List-Treatment as Usual, No intervention-treatment as usual; Behavioral
Lead sponsor: Maurizio Fava, MD; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Sham Genetic Feedback; Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder
Interventions: duloxetine hydrochloride, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 65 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 23
States / cities: Pasadena, California • Sherman Oaks, California • Hamden, Connecticut + 20 more

Conditions: Major Depressive Disorders
Interventions: amibegron (SR58611A), placebo, paroxetine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Major Depressive Disorder
Interventions: Tai Chi; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression
Interventions: Omacor (omega-3-acid ethyl esters); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 40 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Smoking, Depression
Interventions: Smoking Cessation Treatment, Nicotine Replacement Therapy, CBASP; Behavioral · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bipolar Depression
Interventions: ITI-007 (Lumateperone), Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 55
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 52 more

Conditions: Major Depressive Disorder
Interventions: Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation, Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC; Device · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Major Depressive Disorder
Interventions: Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 1,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 35
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Major Depressive Disorder, Post-Traumatic Stress Disorder
Interventions: Ketamine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Severe Postpartum Depression
Interventions: BRII-296, Depo Medrol; Drug
Lead sponsor: Brii Biosciences Limited; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 11
States / cities: Sherman Oaks, California • Torrance, California • Boynton Beach, Florida + 7 more

Conditions: Depressive Disorder, Major, Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
Interventions: CAT, R-CAT; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Post-Traumatic Stress Disorder
Interventions: Treatment as Usual, Virtual Reality Exposure with Stimulus Control; Behavioral
Lead sponsor: Office of Naval Research (ONR); Federal
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Camp Pendlton, California • San Diego, California

Conditions: Major Depressive Disorder
Interventions: paroxetine CR; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 71
States / cities: Birmingham, Alabama • Fairfield, Alabama • Mobile, Alabama + 63 more

Conditions: Major Depressive Disorder
Interventions: PDC-1421 Capsule; Drug
Lead sponsor: BioLite, Inc.; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression
Interventions: riluzole; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depressive Disorder, Major
Interventions: SEP-225289, Venlafaxine, placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 51
States / cities: Little Rock, Arkansas • Arcadia, California • Beverly Hills, California + 43 more

Conditions: Major Depressive Disorder, Depression
Interventions: Cognitive Behavioral Therapy (CBT), Active Whole-Body Hyperthermia (Active WBH), Sham Whole-Body Hyperthermia (Sham WBH); Behavioral · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Antidepressant Effects of NR2B in Major Depression

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

Adaptation of Dialectical Behavior Therapy Skills-Groups for Individuals With Suicidal Ideation and Depression

Electrophysiological Correlates of Cognition in Depression

A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients

Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

Tai Chi Training for Treating Depressed Chinese Americans

Omacor for Perimenopausal Depression

Smoking Cessation for Depressed Smokers

Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression

Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression

VA Augmentation and Switching Treatments for Improving Depression Outcomes

Imaging SV2A in Mood Disorders

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

In-person vs. Remote Wellness Support

Virtual Reality (VR) Therapy for Post-Traumatic Stress Disorder (PTSD)

Major Depressive Disorder Study In Adults

A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

Riluzole to Treat Major Depression

A Safety, Efficacy and Tolerability Study of SEP-225289

HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2